Choudhary Gajendra, Prajapat Manisha, Kumaravel J, Prabha Praisy K, Sarma Phulen, Handa Vrishbhanu, Kaur Harminder, Patel Ajay Prakash, Medhi Bikash
Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Indian J Pharmacol. 2022 Jan-Feb;54(1):41-45. doi: 10.4103/ijp.ijp_955_21.
The new omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in South Africa in November 2021 has been declared as a Variant of Concern by the World Health Organization. This variant has been found to carry multifold mutations that have not been observed in any of the variants detected so far. The majority of these mutations are present in spike protein, contributing to its ability to escape the currently available neutralizing antibodies and vaccines, as well as increasing the chances of reinfection. This brief communication provides an insight into mutations detected in the omicron variant and their impact on currently available interventions against SARS-CoV-2 and the need for a booster dose. We also discuss the severity status of infection due to this variant. Additionally, we highlight the hypothesis supporting the association of high HIV prevalence and the appearance of the omicron variant of SARS-CoV-2 in immune-compromised individuals.
2021年11月在南非出现的新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎变种已被世界卫生组织宣布为关注变种。已发现该变种携带多种此前在任何已检测变种中均未观察到的突变。这些突变大多数存在于刺突蛋白中,使其能够逃避目前可用的中和抗体和疫苗,同时增加了再次感染的几率。本简短通讯深入探讨了在奥密克戎变种中检测到的突变及其对目前针对SARS-CoV-2的干预措施的影响以及加强针的必要性。我们还讨论了该变种导致的感染严重程度状况。此外,我们强调了支持高艾滋病毒流行率与免疫功能低下个体中出现SARS-CoV-2奥密克戎变种之间关联的假说。